Wang Rong, Pan Sisi, Song Xia
The Second Department of Respiratory, Shanxi Provincial Cancer Hospital, Taiyuan 030000, China.
The Second Clinical Medical College of Shanxi Medical University, Taiyuan 030000, China.
Zhongguo Fei Ai Za Zhi. 2022 Mar 20;25(3):174-182. doi: 10.3779/j.issn.1009-3419.2022.101.06.
With the rapid development and wide application of next generation sequencing (NGS) technology, a series of researches have revealed that concurrent genetic alterations play an important role in the response and resistance of epidermal growth factor receptor (EGFR)-mutant NSCLC to EGFR-tyrosine kinase inhibitor (TKI). Besides, TP53 mutation is the most common co-mutation gene in EGFR-mutant NSCLC, which has been proved to confer a worse prognosis in EGFR-mutated patients treated with first, second and third generation of EGFR-TKIs. Currently, it is still being explored how to select the best treatment strategies for patients with concomitant presence of TP53 mutation in EGFR-mutant NSCLC. Here, we review the literature on recent research progress of TP53 concurrent mutation in EGFR-mutant advanced NSCLC. .
随着下一代测序（NGS）技术的迅速发展和广泛应用，一系列研究表明，同时发生的基因改变在表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）对EGFR酪氨酸激酶抑制剂（TKI）的反应和耐药性中起重要作用。此外，TP53突变是EGFR突变NSCLC中最常见的共突变基因，已被证明在接受第一代、第二代和第三代EGFR-TKI治疗的EGFR突变患者中预后较差。目前，如何为EGFR突变NSCLC中同时存在TP53突变的患者选择最佳治疗策略仍在探索中。在此，我们综述了关于EGFR突变晚期NSCLC中TP53共突变的最新研究进展的文献。
